Form 8-K - Current report:
SEC Accession No. 0001213900-24-094349
Filing Date
2024-11-05
Accepted
2024-11-05 09:08:24
Documents
16
Period of Report
2024-11-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220029-8k_inmed.htm   iXBRL 8-K 29877
2 NEWS RELEASE, DATED NOVEMBER 5, 2024 ea022002901ex99-1_inmed.htm EX-99.1 14621
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5102
  Complete submission text file 0001213900-24-094349.txt   271606

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20241101.xsd EX-101.SCH 3265
5 XBRL DEFINITION FILE inm-20241101_def.xml EX-101.DEF 26195
6 XBRL LABEL FILE inm-20241101_lab.xml EX-101.LAB 35952
7 XBRL PRESENTATION FILE inm-20241101_pre.xml EX-101.PRE 24853
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0220029-8k_inmed_htm.xml XML 4252
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 241425942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)